Disc Medicine (NASDAQ: IRON) CMO sells 7,378 shares under 10b5-1 plan

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Medical Officer William Jacob Savage reported two open-market sales of common stock. On March 2, he sold 4,392 shares at a weighted average price of $65.5218 per share, and 2,986 shares at a weighted average price of $66.4090 per share, totaling 7,378 shares sold. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 2, 2025. After the sales, he continued to hold 85,211 shares directly.

Insider Trade Summary

Net Seller: 7,378 shares ($486,069)

Net Sell 2 txns

Insider Savage William Jacob

Role Chief Medical Officer

Sold 7,378 shs ($486K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,392	$65.5218	$288K
Sale	Common Stock	2,986	$66.409	$198K

Holdings After Transaction: Common Stock — 88,197 shares (Direct)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.03 to $66.88, inclusive.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage William Jacob

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		4,392	D	$65.5218(2)	88,197	D
Common Stock	03/02/2026		S(1)		2,986	D	$66.409(3)	85,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.03 to $66.88, inclusive.

	By: /s/ Rahul Khara, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Disc Medicine (IRON) disclose in this Form 4?

Disc Medicine reported that Chief Medical Officer William Jacob Savage sold 7,378 shares of common stock in open-market transactions. The sales occurred on March 2 at weighted average prices around the mid-$60s per share, and he retained a significant remaining direct shareholding afterward.

How many Disc Medicine (IRON) shares did the CMO sell and at what prices?

The CMO sold 4,392 shares at a weighted average price of $65.5218 and 2,986 shares at a weighted average price of $66.4090. The trades were executed in multiple transactions within disclosed intraday price ranges around those averages.

Does the Disc Medicine (IRON) Form 4 indicate a trading plan for these sales?

Yes. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on October 2, 2025. Such plans pre-schedule trades, helping insiders systematically sell shares without making real-time trading decisions based on nonpublic information.

How many Disc Medicine (IRON) shares does the CMO hold after the reported sales?

After the reported sales, Chief Medical Officer William Jacob Savage directly holds 85,211 shares of Disc Medicine common stock. The filing shows his ownership declining from 88,197 shares after the first transaction to this new balance following completion of the second sale.

Were the Disc Medicine (IRON) insider sales single trades or multiple transactions?

Each reported line reflects a weighted average price across multiple individual trades. The first block sold between $65.00 and $65.98 per share, while the second sold between $66.03 and $66.88, according to the detailed price range disclosures in the footnotes.

Who executed the Disc Medicine (IRON) stock sales reported in this Form 4?

The sales were executed by William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc. He is the reporting person on the Form 4 and held the shares directly, with the transactions classified as open-market sales of common stock.